Publications
Driving Precision Oncology Research
Every day, new discoveries confirm the increasing and important role biomarker analysis and tumor profiling have in personalized cancer care. We contribute to the body of research in oncology to advance the understanding of molecular science and further enable the delivery of precision medicine.
FEATURED
-
Characterization of plasma cell-free DNA variants as of tumor- or clonal hematopoiesis-origin in 16,812 advanced cancer patients
– Caris Life Sciences
Abstract Purpose: Plasma-based liquid biopsy tests can detect tumor-specific genetic alterations and offer many advantages that complement tissue-based Comprehensive Genomic Profiling (CGP). However, age-related clonal hematopoiesis (CH) mutations can confound liquid biopsy results and potentially lead to incorrect therapy choice. Experimental Design: We assessed the landscape of 16,812 liquid profiles across 49 cancer types using the Caris… […]
Filter By
Discover
More
Caris is actively delivering on the promise of precision medicine and our pipeline reflects our future tests and molecular science-based solutions to help patients and improve the human condition.
With one of the largest, multi-modal databases of combined molecular and clinical outcomes data in the world, Caris applies highly sophisticated AI bioinformatics and machine learning capabilities on this massive database to create novel, clinically relevant solutions to classify cancer at the molecular level and predict patient response in ways never before possible.
Have questions?
"*" indicates required fields